Intellectual Property Policy
Kean University
Approved 12.4.10 and Amended and Restated 9.14.15
Kean University Board of Trustees
1442320-2 Page 6 of 7
disclosable. The representatives of the Faculty Senate may disclose the subject of the matters
discussed, without disclosing the contents, in order to report back to the organization. Breach of this
covenant shall be considered serious misfeasance, if not malfeasance and dealt with accordingly.
IPC shall meet at least quarterly. Additionally, upon the issuance of a ten day notice to the other
members, made at the request of the Chair of the Committee, IPC may convene at any time. IPC
recommendation shall not issue from IPC absent a quorum of the Committee taking part in deliberations
and recommendation. Three (3) members of the Committee shall constitute a quorum.
C. Executive Committee for Technology Development
The University’s commercialization determination will be the primary responsibility of the ECTD. In this
regard, ECTD will consult with OTC, IPC, independent scientific and technology transfer experts as
needed and, as appropriate, other university officials and render a decision as soon as practicable on
behalf of Kean, published to the appropriate parties, including the inventor(s), as to whether to file a
patent application, the protective processes to be employed, and, when and as appropriate, the manner
and method of commercialization intended.
1. Appeal of Commercialization Determination
If the inventor(s) disagree(s) with the determination concerning commercialization of the invention or
discovery, the inventor(s) may, as the exclusive process for this type of challenge, appeal this
determination to the President. This appeal, stating all the facts and bases for the inventor’s position,
must be in writing and filed within thirty (30) days following the date of notice of the determination
being challenged. The President shall review the appeal and shall issue a decision setting forth the
reasons therefore, if there is a substantial basis in fact, policy or law for either reconsideration or
adjustment. The application will be remanded to ECTD for reconsideration based upon the President’s
decision. The decision of the President will be final and binding. Remand shall be available only once
per ECTD review and accompanying Kean commercialization decision. In the case of a
commercialization decision, the President’s decision will be implemented.
2. Additional Responsibilities of ECTD
In addition to the ultimate commercialization determinations that are the responsibility of ECTD, it shall
provide executive oversight of the program, directing concerns raised by interested parties (e.g.
inventors, IPC, OTC, State of New Jersey, investors, labor constituents, legal counsel) to proper
resolution, either through decision, publication and effectuation or through employing appropriate
resources to resolve disputes or unsettled controversies. ECTD will provide expertise or identify those
who are responsible for same and where appropriate, will identify and facilitate university authorized
alternatives to matters brought before it.
NOTE: ECTD’s responsibilities and concomitant authority do not subjugate standing policy and
procedure for dispute resolution; it offers administrative streamlining services and, where appropriate,
potential alternative(s) to standing practices and protocols.